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Cutaneous melanoma is highly immunogenic, yet primary melanomas and metastases develop successfully in otherwise
immunocompetent patients. To investigate the local immunosuppressive microenvironment, we examined the presence of
suppressor T lymphocytes and tolerising dendritic cells (DCs), the expression of immunosuppressive cytokines (IL-10, TGFb1 and
TGFb2) and the enzyme indoleamine 2,3-dioxygenase (IDO) using qRT–PCR and immunohistochemistry in primary skin
melanomas, negative and positive sentinel lymph nodes (SLN), and lymph nodes with advanced metastases. Our results indicate that
tolerogenic DCs and suppressor T lymphocytes are present in melanoma at all stages of disease progression. They express
transforming growth factor b receptor 1 (TGFbR1), and are therefore susceptible to TGFb1 and TGFb2 specifically expressed by
primary melanoma. We found that expression of IDO and interleukin 10 (IL-10) increased with melanoma progression, with the
highest concentration in positive SLN. We suggest that negative SLN contain immunosuppressive cells and cytokines, due to
preconditioning by tolerogenic DCs migrating from the primary melanoma site to the SLN. In primary melanoma, TGFb2 is likely to
render peripheral DCs tolerogenic, while in lymph nodes IDO and TGFb1 may have a major effect. This mechanism of tumour-
associated immunosuppression may inhibit the immune response to the tumour and may explain the discrepancy between the
induction of systemic immunity by anti-melanoma vaccines and their poor performance in the clinic.
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Regulation of immune responses is essential to avoid autoimmu-
nity, but there is a fine balance between switching off deleterious
immune responses and suppressing beneficial ones. This is
particularly true in cancer, where suppression of the immune
response assists tumour growth and metastases. Both CD8þ and
CD4þ T lymphocyte subsets can downregulate immune responses
via direct interactions with antigen-presenting cells (APC), or
through APC-independent pathways, for example by secreting
immunoregulatory cytokines (Filaci and Suciu-Foca, 2002; Jonuleit
and Schmitt, 2003). These regulatory or suppressor lymphocytes
can be identified by expression of the transcription factor FoxP3
(Filaci and Suciu-Foca, 2002; Suciu-Foca et al, 2005).
Dendritic cells are involved in immunosuppression in numerous
ways, both at the level of clonal deletion in the thymus and in
the development of peripheral tolerance. Dendritic cell-derived
immunosuppression is antigen dependent and can result either
from antigen presentation by immature dendritic cells (DCs) that
lack sufficient accessory molecules, lack of proinflammatory
cytokines (Lutz and Schuler, 2002; Enk, 2005), the involvement
of immunoglobulin-like transcripts 3 and 4 (ILT3 and ILT4) on
tolerogenic DCs and secretion of immunosuppressive agents, such
as indoleamine 2,3-dioxygenase (IDO), interleukin 10 (IL-10) and
transforming growth factor b (TGFb) (Manavalan et al, 2003; Enk,
2005). Additionally, immature DCs can differentiate into tolero-
genic DCs under the influence of IL-10, TNFa and regulatory T
lymphocytes (Enk, 2005). Interactions between immunosuppres-
sive T lymphocytes and tolerogenic DCs are numerous, and
generally result in cytokine-driven immunomodulatory responses
(Manavalan et al, 2003; Enk, 2005; Suciu-Foca et al, 2005).
Cutaneous melanoma has long been recognised as an immuno-
genic tumour that successfully evades immune recognition while
paradoxically, spreads through the lymphatic system. As yet no
truly successful anti-melanoma vaccine has been developed,
although various strategies have been tested. In general, numerous
tumour-reactive T lymphocytes can be detected in the patient’s
blood following vaccination, but tumour growth is unaffected
(Arienti et al, 1996; Lee et al, 1998; Baurain et al, 2000; Appay et al,
2006). One explanation is that the tumour microenvironment is so
immunosuppressive that any incoming effector cell is impeded
(Appay et al, 2006). Proposed mechanisms for melanoma-derived
immunosuppression include the secretion of TGFb, IL-10 and IDO,
which have been found in patients’ blood, primary melanomas and
sentinel lymph nodes (SLN) (Reed et al, 1994; Real et al, 2001; Lee
et al, 2003, 2005; Redondo et al, 2003). Additionally, levels were
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sfound to correlate with tumour progression and invasiveness
(Reed et al, 1994; Conrad et al, 1999). This suppression is likely to
be local to the tumour, but could affect immune cells in draining
lymph nodes as well.
The role of TGFb in tumour growth promotion and immuno-
suppression has been extensively studied. This cytokine can be
produced by tumour cells, and can act in an autocrine and
paracrine manner (Clark and Coker, 1998). Immune cells such as
T lymphocytes and DCs have also been reported to secrete various
isoforms of TGFb, and the presence of this cytokine promotes an
immunosuppressive phenotype in both of these cell types (Chen
and Wahl, 2003; Ghiringhelli et al, 2005). Interleukin 10 exerts
suppressive effects on a wide range of immune cells, including
T lymphocytes and DCs. It can be produced by regulatory
T lymphocytes and by tumour cells (Enk, 2005). Indoleamine
2,3-dioxygenase is an enzyme produced mainly by APC of myeloid
origin that suppresses T lymphocyte-related antigen-specific
immune responses (Mellor and Munn, 2004). It has also been
associated with disease progression in various tumour types,
including colorectal cancer (Brandacher et al, 2006), haemangioma
(Ritter et al, 2003) and melanoma (Harlin et al, 2006).
As both T lymphocytes and DCs are present in close proximity
to melanoma and even within the tumour mass itself (Vermi et al,
2003; Bernsen et al, 2004; Polak et al, 2005), they are directly
exposed to tumour-derived immunosuppressive cytokines. Indeed,
alterations in DC numbers and maturity have been reported in
SLN compared with non-SLN (Lana et al, 2001; Botella-Estrada
et al, 2005). To investigate this further, we have compared matched
samples of primary skin melanoma and negative and positive SLN
for evidence of immunosuppression. We have used quantitative
PCR and immunohistochemistry (IHC) to enumerate the cytokines
and immunosuppressive molecules within tumour and draining
lymphoid tissue to determine the extent of immunosuppression in
these tissues and to identify the key components.
MATERIALS AND METHODS
Patients and samples
Fifteen primary melanoma samples, 22 matching SLN and 19
lymph nodes with melanoma deposits from a separate cohort of
patients were included in the study. In analysed positive SLN, the
melanoma micrometastases were present, while in lymph nodes
with melanoma deposit, the tumour replaced more than 75% of the
lymph node. Among these, we identified 11 matched samples of
individual progressing melanomas, including three primary skin
melanomas for which both negative and positive SLN were
available. The remaining eight matched pairs comprised seven
pairs of skin melanoma and negative SLN and one additional
pair of negative and positive SLN (data not shown). As a cancer
unrelated control tissue, we used eight pairs of tonsils routinely
removed in therapeutic tonsillectomies. All samples analysed by
qRT–PCR and IHC came from formalin-fixed paraffin-embedded
tissue (FFPE), obtained from the Portsmouth Hospitals archive.
The patients gave their consent for the use of archival tissue for
research purposes and the study was conducted according to
MultiCentre and Local Research Ethics Committee regulations.
The choice of a particular block was made on the basis of careful
microscopic evaluation.
RNA extraction and preparation of cDNA
Five 10mm sections were cut from each block for RNA recovery.
The tissue was dewaxed and rehydrated by sequential washes first
through xylene and then ethanol at 100, 90 and 70%. Ribonucleic
acid was extracted using the Ambion RecoverAll Total Nucleic
Acid Isolation kit (no. 1970, Ambion, Huntington, UK) according
to the manufacturer’s protocol. To improve the yield of RNA,
each sample was additionally purified in a filtration step before
the extraction, using Nucleospin filter columns (Nalgene, VWR
international, Leicestershire, UK), and microcentrifuged at 13000g
for 1min. The flow-throughs were collected and RNA extracted
according to the Ambion protocol. The quantity and purity of
extracted RNA was assessed using a NanoDrop-2000 spectro-
photometer. Based on these measurements, the RNA sample
concentration was adjusted to 100ngml
 1 and aliquoted into RT
reaction tubes, with a separate tube for the RT-negative control
mix. The RT master mix was prepared at twice the concentration
using the ABI High-Capacity cDNA Archive kit (Applied
Biosystems, Warrington, UK) and added to prepared RNA
aliquots. The RT reaction was carried out in a pre-programmed
Hybaid OMN-E Thermal Cycler, in a two-step reaction, 10min at
room temperature followed by 120min at 371C.
The FFPE tissue PCR reaction
The PCR reaction was carried out using the Taqman primer probe
system, suitable for FFPE tissue, as primers are designed to flank
regions of nucleic acid strands smaller than 150 bases in length. To
ensure that our quantitative results were RNA damage indepen-
dent, all of the data were analysed as a ratio between target gene
expression and least variable housekeeping gene expression,
assuming that any RNA damage due to fixation problems is
random (Rupp and Locker, 1988; Godfrey et al, 2000; Cronin et al,
2004) and would affect the least variable housekeeping gene to the
same degree as target genes. After testing four different house-
keeping genes, HMBA was selected as the control housekeeping
gene for tumour samples because its cycle threshold value showed
the least variation between samples and its efficiency closely
matched the transcription efficiency of the target genes. As the
signal threshold cycle (CT) is often delayed in cDNA from FFPE
material the standard Taqman PCR protocol was extended to 50
cycles. The best housekeeping gene CT was used as a sample
inclusion criterion: all samples with CT above 37.5 were excluded
from further analysis. We assessed the intra and inter-assay
reproducibility in preliminary experiments, and as the results were
satisfactory (difference in CT between triplicate wells lower than
0.5 CT), we reduced the repetitions to single-well measurements.
The PCR reaction was carried out using the Taqman primer
probe system (Applied Biosystems), optimised for short mRNA
sequences, and thus optimal for FFPE material. The Taqman
primer probe FAM490-conjugated reagent was diluted 1:10 with
Taqman Master Mix (both from Applied Biosystems) and 11mlo f
the mix was distributed into a 96-well PCR plate. The cDNA
concentration was measured using a NanoDrop 2000 spectophoto-
meter, adjusted to 300ngml
 1 and 9ml added to each well. We
tested the following target genes: the cytokines TGFb1, TGFb2 and
IL-10 (Taqman primer probes codes: Hs00171257, Hs00234244 and
Hs00174086, respectively), the enzyme IDO (Hs00158032), two
membrane-bound molecules, ILT3 and ILT4 and FOXp3, a nuclear
transcription factor (Hs00429000, Hs00275975 and Hs00203958).
The plate was designed to accommodate all the target genes, best
housekeeping gene, sample RT-negative controls and no template
controls. To ensure identical reaction conditions for matched-pair
samples, all samples from one patient were run in the same PCR
plate. For each run, a matching well factor plate (BioRad well
factor reagent; BioRad, Herts, UK) was diluted 1:10 in nuclease-
free water (Promega, Southampton, UK). Both loaded plates were
spun down to remove any air bubble. A BioRad quantitative PCR
thermal cycler (I-cycler) was used together with BioRad software.
The standard Taqman protocol comprising well factor plate
measurements (six cycles), followed by plate replacement and
enzyme activation, 2min at 501C, and 10min double-stranded
cDNA denaturation at 951C, was extended from 40 to 50 cycles of
repeated 15s per 951C and 1min per 601C incubations.
Tolerogenic DC in melanoma
ME Polak et al
1880
British Journal of Cancer (2007) 96(12), 1879–1887 & 2007 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sqPCR data analysis
Before carrying out data analysis on qRT–PCR results, amplifica-
tion plots were checked to confirm that housekeeping, target genes
and negative controls appeared as expected. The best house-
keeping gene CT was determined and all samples for which the
best housekeeping gene CT exceeded 37.5 cycles were excluded
from further evaluation. For all the genes for which the CT
exceeded 40 cycles, the PCR efficiency analysis was repeated, and
only samples whose amplification plot slopes did not differ from
the best housekeeping gene CT were included in further analysis.
Relative target gene expression was then calculated according
to the expression 2
 DCT, where DCT equals the difference between
target gene CT and reference gene (best housekeeping gene) CT.
The median relative gene expressions of each target were used
in further comparisons. The gene expression differences between
groups were tested in one-parameter multivariant analysis
ANOVA. Separately, comparisons within two groups of matched
samples were performed, namely three complete matched samples,
including primary melanoma, negative and positive SLN and seven
negative SLN vs positive SLN matched pairs. We used the
Wilcoxon matched pair test for statistical analysis.
Immunohistochemistry
To assess whether the gene expression data matched the actual
protein production, we performed immunostaining for TGFb2,
TGFbR, IDO and FOXp3 on skin and SLN sections. The primary
antibodies were purchased from Abcam (Cambridge, UK) (TGFb2,
FOXp3), Novocastra (Newcastle upon Tyne, UK) (TGFbR) and
Chemicon (Chandlers Ford, UK) (IDO, rabbit polyclonal). Enzy-
matic digestion (TGFb2), microwave pretreatment (IDO) and
pressure cooking were included for antigen retrieval purposes. To
evaluate the presence of DCs in the tissues examined, we used the
anti-FXIIIa antibody from Calbiochem (Nottingham, UK), (after
pressure cooking pretreatment), as this is a standard dermal DC
marker antibody in our laboratory (Polak et al, 2005). Double
staining for FXIIIa and IDO performed in chosen SLN enabled us
to identify cells that secreted IDO. To avoid confusion with
melanin, we used the red chromogen, Fuchsin, for visualisation of
positive staining. For double staining, performed in SLN without
significant melanoma micrometastases, we used combined DAB
and Fuchsin visualisation systems.
RESULTS
Stage-related expression of immunosuppressive cell
markers and soluble molecules
Immunological cell infiltrates In initial experiments, cDNA
derived from unrelated primary cutaneous melanoma, positive
and negative SLN, lymph nodes with melanoma deposits and tonsil
were compared. To evaluate the subtypes of immunosuppressive
cells associated with progression of cutaneous melanoma, we
measured FOXp3, a transcription factor found in both suppressor
and regulatory T lymphocytes (Suciu-Foca et al, 2005), and ILT3
and ILT4 that are associated with tolerogenic DCs (Manavalan
et al, 2003). High levels of FoxP3 and ILT3 expression were
observed in more than 85% of the samples in each category,
including the primary tumour, and were expressed at levels
roughly equivalent to the housekeeping gene (Figure 1; HK¼1.00).
Expression of ILT4 was generally about a 100 times lower and often
at borderline detection levels, and did not differ markedly between
sites (data not shown). Both FoxP3 and ILT3 showed similar
expression patterns and were detected in all four melanoma sites,
but were highest in positive SLN (Figure 1A and B). The presence
of FoxP3-positive lymphocytes was confirmed by IHC. FoxP3-
positive cells were present as single positive cells within the
lymphatic tissue in SLN as well as among tumour cells in primary
melanoma of the skin (Figure 2C).
Expression of immunosuppressive cytokines and IDO As secreted
soluble molecules can promote tumour-derived immunosuppres-
sion, we examined the expression of two isoforms of TGFb, which
can be produced by melanoma cells and by suppressor or
regulatory lymphocytes; IL-10, produced by DCs and suppressive
or regulatory T lymphocytes and IDO, produced mainly by APC of
myeloid origin. Expression of all four molecules was detected in all
sites examined: expression of the two isoforms of TGFb being the
most ubiquitous (TGFb1 was present in 100% of cases, TGFb2i n
92.3% of the negative SLN and in 100% in the three other
categories). Transforming growth factor b1 had by far the highest
overall expression and was the most uniform at different stages of
melanoma progression (Figure 1C). Despite a noticeable increase
in TGFb1 expression after progression into the negative SLN, no
further enhancement was observed with melanoma metastasis to
the lymph nodes. Transforming growth factor b2 expression was
highest in primary skin melanoma and lowest in negative SLN,
indicating its release by tumour cells themselves. This was
confirmed by IHC, which showed that TGFb2 is primarily tumour
cell associated (Figure 2). Expression of IDO was detected in 75%
of primary cutaneous melanoma samples and positive SLN, and in
100% of negative SLNs and lymph nodes with extensive melanoma
metastasis. Interleukin 10 was detected in between 83 and 88% of
cases at each stage. As with ILT3 and FOXp3, expression of both
IL-10 and IDO increased with melanoma progression from skin
into the lymph nodes, the peak occurring in positive SLN (Figure
1E and F). This was most striking for IDO, where levels increased
by a factor of four between skin and negative SLN, and increased
again by a similar amount between negative and positive SLN.
Expression of IDO by FXIIIa-positive DCs was confirmed by IHC
(Figure 2D).
In lymph nodes with advanced metastasis, there was generally a
decrease in the levels of all molecules investigated, although these
remained detectable and were in some cases highly expressed. This
observation might reflect differences in the ratio of lymphoid vs
tumour tissue in these samples although IHC showed both FoxP3
and tolerogenic DCs to be present in both tissue compartments.
Expression of immunosuppressive molecules in tonsil As a
control, we examined expression of all of the markers associated
with immunosuppression in tonsils. These were chosen because
of their accessibility and because they are associated with the
mucosal immune system, and might therefore naturally be
expected to have an immunosuppressed phenotype. We observed
less variation between samples in tonsil compared with melanoma.
All of the markers investigated were also found in tonsil, although
ILT4 was again present at very low levels. Median expression of
FOXp3, ILT4 and IDO was comparable in tonsils and in negative
SLN, whereas expression of ILT3 was higher in negative SLN
(P¼0.025; Figure 1A). Median levels of both TGFb1 and IL-10
were higher in negative SLN than in tonsils (the difference
statistically significant for IL-10, P¼0.044; Figure 1F), while
expression of TGFb2 was highest in tonsil (Figure 1D; P¼0.012).
Analysis of matched melanoma samples
The general trend observed in consecutive stages of melanoma was
a gradual build up of the immunosuppressive markers ILT3,
FOXp3, IL-10 and IDO, with peak expression occurring in positive
SLN. This was in contrast to TGFb1 that remained high throughout
and TGFb2 that was highest in the primary tumour. To verify these
observations, we identified and examined melanoma samples from
the same patients, three of which included skin, negative and
positive SLN (Figure 3) and seven additional pairs of matched skin
and negative SLN samples (Figure 4).
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matched pair samples. We observed higher expression of ILT3
(Po0.112), FOXp3 (Po0.039), IDO (Po0.037) and IL-10
(Po0.047) in negative SLN compared with skin samples (eight
matched pairs in total for ILT3 and nine matched pairs in total
for FOXp3, IDO and IL-10; Figures 3 and 4). In the three sets of
samples containing positive SLN, the expression of all four
molecules further increased in positive SLN (Figure 3).
It is of note that markers indicative of immunosuppression are
also seen in negative SLN. In particular, the expression of IDO
increased between primary cutaneous melanoma and negative
SLN by median 29.11-fold in five out of seven cases examined
(Po0.037), and IL-10 by median 6.37-fold (Po0.047).
TGFb1 was also increased in the matched negative SLN
compared with skin samples (Figures 3 and 4), with a median
fold increase of 10.55 (Po0.004). This was followed by a noticeable
drop in positive SLN in all three of the matched series of samples
(Figure 3). In contrast, relatively high levels of TGFb2 in skin were
followed by a drop in the negative SLN in all but one of the pairs
examined, although the magnitude was far less pronounced
(median value 2.46; Po0.04).
Activation status of suppressor lymphocytes and tolerogenic
DCs Direct comparisons of immune cell infiltrates in skin, SLN
and lymph nodes with advanced metastasis are difficult due to
differences in the relative amounts of lymphatic tissue they
contain. However, by comparing changes in the levels of each of
the markers of immunosuppression at each of the stages of the
disease it is possible to gain a better insight into how
immunosuppression might develop as the tumour progresses
(Table 1).
Dendritic cells present in negative SLN appear to be more
tolerogenic than those within the primary tumour because,
although the median expression of ILT3 remains stable, the
expression of both IDO and TGFb1 increases (IDO 4.02, TGFb1
2.37; Table 1). This was also seen in the matched tissue analysis
where the ratios of median relative expression in negative SLN
and skin for ILT3, IDO and TGFb1 are respectively 2.37, 29.11
and 10.55. During progression from negative to positive SLN,
expression of all markers of immunosuppression (apart from
TGFb1) is increased. This is particularly true for ILT3 and IDO,
which are increased approximately four-fold (Table 1). Suppres-
sor/regulatory T cells, as measured by FOXp3, increase with
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Figure 1 Stage-related expression of immunosuppressive molecules in cutaneous melanoma. The graphs in the panel show expression of (A) ILT3, a
tolerogenic DC marker, (B) FOXp3, a regulatory and suppressive T lymphocyte marker, (C, D) two isoforms of TGFb, an immunoregulatory cytokine, (E)
IDO, an immunoregulatory enzyme produced by APC of myeloid origin and (F) IL-10, an immunosuppressive cytokine produced by T lymphocytes and
tolerogenic DCs at four stages of melanoma progression, that is, primary skin melanoma, negative SLN, positive SLN and lymph nodes with advanced
melanoma metastases. The dots indicate relative expression of a target gene in comparison with the reference gene (HMBS) calculated as 2
 DCT, where
DCT¼CTtarget CTHMBS. Each dot represents the value for one sample, and the horizontal line indicates the median value for the site. The expression of
ILT3, FOXp3, IL-10 and IDO increases with melanoma progression into SLN, with the peak concentration in the positive SLN, while concentration of
TGFb1 remains stable between negative and positive SLN, after initial intense increase in negative SLN. The concentration of TGFb2 is the highest in primary
skin melanoma, and is restored in SLN only after the invasion of melanoma. The P-values for statistically significant differences in molecule expression are
shown where relevant. The last set of data presents expression of tolerogenic cell markers in tonsils, used as control lymphatic tissue.
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negative to positive SLN (4.29-fold; Table 1). This is not however
reflected by a proportional increase in IL-10. Transforming growth
factorb1, which can be a sign of T lymphocyte activity, is
comparable to FOXp3 in negative SLN vs skin (2.37 and 1.74,
respectively; Table 1), but expression of TGFb1 remains stable,
with progression to positive SLN, while expression of FOXp3
increases 4.29-fold (Table 1). In lymph nodes with advanced
metastasis there is less evidence of immunosuppression compared
with earlier stages; a five-fold decrease in ILT3 expression and an
almost 10-fold decrease in IDO expression (Table 1). When
comparing matched skin-negative SLN pairs, the IL-10 and FOXp3
A B
D C
E
GH
F
Figure 2 Expression of immunosuppressive cytokines and tolerogenic cell markers in melanoma at different stages of progression. To confirm the PCR-
detected expression of mRNA for the cell markers and immunosuppressive cytokines examined, we performed IHC on sections from the same block as that
used for RNA extraction. To avoid confusion with melanin, a red chromogen (Fuksin, Dako, UK) has been used and representative photographs taken to
illustrate the findings. The images are as follows, with the original magnifications in parentheses: (A) FXIIIaþ cells within the tumour tissue in a lymph node
largely replaced by metastatic melanoma ( 400). (B) TGFb2 expression in by melanoma cells in primary cutaneous melanoma ( 400). (C) TGFbR1
expression by lymphoid cells in primary skin melanoma ( 400). (D) TGFbR1 expression in by lymphoid cells in an SLN positive for a melanoma
micrometastasis (not shown) ( 400). (E) Double staining for IDO (red) and FXIIIa (brown) in a negative SLN ( 400). (F) Double staining IDO (red)
FXIIIa (brown) in a melanoma-positive SLN ( 400). (G) Expression of FoxP3þ, a nuclear transcription factor regulatory and suppressive T lymphocyte
marker, in primary skin melanoma ( 1000). (H) Expression of FoxP3þ lymphocytes in a melanoma-positive SLN ( 1000).
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TGFb1 relative expression in paired negative sentinel LN is 10.55-
fold.
Expression of all the targets was greatly reduced in metastatic
lymph nodes. Levels of TGFb1 and ILT3 were in fact very similar to
those seen in the primary skin tumours. The expression of FOXp3
was twofold lower (ratio 0.53; Table 1); however, DCs in lymph
nodes with advanced melanoma metastasis have a higher
expression of IDO than primary skin tumours (ratio 1.63; Table 1).
Expression of TGFbR1 As TGFb seems to be an important
component of the immunosuppressive character of melanoma, we
investigated the presence of one of the receptors (TGFbR1), which
is essential for TGFb signal transduction (Kaminska et al, 2005),
in order to determine which cells were able to respond to the
cytokine. Sections from all four sites were stained for TGFbR1
by IHC and evaluated. We found that staining for TGFbR1 was
very robust, and that many, but not all, melanoma cells were
positive for this receptor. The strongest expression of TGFbR1 was
however observed on the immunological cell infiltrate, both in
lymph node and in skin sections, rather than the melanoma cells
(Figure 2B).
DISCUSSION
As cutaneous melanoma occurs in the presence of an intact
immune system, it must necessarily develop mechanisms to evade
the immune response. These include the release of immuno-
suppressive cytokines that can further modulate antigen-specific
immune cells. We have investigated the relationship between
active immunosuppression and melanoma progression. We
detected the presence of suppressor/regulatory T lymphocytes
and tolerogenic DCs at all stages of melanoma development.
FOXp3-positive, IL-10 producing T lymphocytes were recently
reported in tumour, blood and ascites from patients with advanced
melanoma, and were associated with melanoma-related immuno-
suppression (Appay et al, 2006; Cesana et al, 2006; Harlin et al,
2006). As well as FOXp3 we have also demonstrated expression of
ILT3, a marker of tolerogenic DCs and have correlated markers of
local immunosuppression with melanoma progression. The level
of immunosuppression increased from skin, through negative
SLN, with the peak concentration of lymphatic cell markers and
immunosuppressive molecules in positive SLN. Direct compa-
risons of immune cell infiltrates in skin, SLN and lymph nodes
with advanced metastasis are difficult due to differences in the
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Figure 3 Changes in expression of immunosuppressive molecules during the disease progression in three matched melanoma samples. The graphs in the
panel indicate changes in the expression of (A) ILT3, (B) FOXp3, (C) TGFb1( D) TGFb2, (E) IDO and (F) IL-10 at three stages of melanoma progression,
that is, primary cutaneous melanoma, negative SLN and positive SLN, each data set obtained from matched sites from one patient. Values on the y-axis
represent relative expression of a target gene in comparison with the reference gene (HMBS) calculated as 2
 DCT, where DCT¼CTtarget CTHMBS. The
values of relative expression of DC and T lymphocyte markers (ILT3 and FOXp3) increase with melanoma progression in two cases, whereas expression of
IDO and IL-10 increase in all three cases. The changes in expression of TGFb1 and TGFb2 are negatively correlated, and while the value for TGFb2 increases
with melanoma invasion to SLN, expression of TGFb1 decreases in positive SLN.
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srelative amounts of lymphatic tissue they contain. However, by
comparing changes in the levels of each of the markers of
immunosuppression at each of the stages of the disease it is
possible to gain a better insight into how immunosuppression
might progress as the tumour progresses. Dendritic cells present in
negative SLN appear to be more tolerogenic than those within the
primary tumour because, although the median expression of ILT3
remains stable, the expression of both IDO and TGFb1 increases by
as much as a factor of 30 in matched samples. Numbers of
suppressor/regulatory T lymphocytes, as measured by FOXp3,
almost double with progression from skin primary to negative
SLN, and there are similar increases in IL-10.
This indicates an increase in tolerogenic DCs and T lymphocytes
activity in comparison with primary skin melanoma. Strikingly,
the expression of TGFb1 was not increased further once melanoma
progressed into the lymph nodes, suggesting that the negative SLN
is already immunosuppressed prior to melanoma metastasis.
In contrast, the much lower expression of TGFb2 is more closely
related to the presence of melanoma cells, and this cytokine is
nearly absent in negative SLN. Our finding supports the hypothesis
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Figure 4 Changes in expression of immunosuppressive molecules in seven matched samples of primary skin melanoma and corresponding negative SLN.
The graphs in the panel indicate changes in expression of (A) ILT3, (B) FOXp3, (C) TGFb1( D) TGFb2, (E) IDO and (F) IL-10 in seven matched pairs of
skin and negative SLN from melanoma patients. Values on the y-axis represent relative expression of a target gene in comparison with the reference gene
(HMBS) calculated as 2
 DCT, where DCT¼CTtarget CTHMBS. The P-values given above each set of data are obtained from a Wilcoxon paired test analysis,
and are significant for all the molecules except ILT3. The observations of note are the very intense increase of TGFb1 expression in negative SLN and
disproportional increase of IDO expression (median 29-fold) in comparison with stable ILT3 expression.
Table 1 Ratios of median relative expression between different stages of melanoma progression
ILT3 ILT4 FOXp3 TGFb1 TGFb2 IDO IL-10
Negative SLN/skin 1.37 0.54 1.74 2.37 0.18 4.02 1.01
Positive SLN/negative SLN 4.00 2.84 4.29 0.97 2.90 3.46 2.00
LN+mel/positive SLN 0.20 0.16 0.07 0.55 0.74 0.12 0.20
LN+mel/skin 1.11 0.25 0.53 1.27 0.38 1.63 0.41
Abbreviations: IDO, indoleamine 2,3-dioxygenase; IL-10, interleukin 10; ILT3, immunoglobulin-like transcript 3; ILT4, immunoglobulin-like transcript 4; LN, lymph node; mel,
melanoma; SLN, sentinel lymph nodes; TGFb, transforming growth factor b.
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sthat the presence of TGFb2 is correlated with melanoma
progression (Reed et al, 1994). This suggests that TGFb2
(produced either directly by melanoma or by associated fibro-
blasts) and not TGFb1 might in fact be the primary melanoma-
derived immunosuppressive factor. As nearly all of the infiltrating
immune cells were positive for TGFb1R, they are potentially
susceptible to TGFb-mediated immunosuppression. Data on the
influence of TGFb2 on APC are scarce, but this cytokine has been
shown to inhibit the antigen presenting abilities of epidermal APC
in mice (Hosoi et al, 1993), and its presence correlated with
tumour progression, despite peripheral antitumour T-cell activity
in glioblastoma patients (Liau et al, 2005).
We suggest that TGFb2 produced by primary melanoma may
convert peripheral DCs into tolerogenic cells. These could then
migrate to the SLN, before any tumour spread takes place and
prime the site for tumour growth, by producing IDO and TGFb1,
and making the SLN an immunoprivileged site suitable for
melanoma metastasis. In studies on mouse and human macro-
phages activated with IFNg to secret IDO, TGFb was shown to
inhibit IDO secretion (Bogdan and Nathan, 1993; MacKenzie et al,
1999). However, it is conceivable that tolerogenic DCs may react
differently to DCs primed to activate immune responses. If this
hypothesis is correct, it would mean that tolerogenic DCs
generated in response to tumour derived cytokines actively
support this process. Once the melanoma actually metastasises,
and the SLN becomes positive, TGFb2 produced by invasive
melanoma cells may further increase the immunosuppression,
resulting in the development or attraction of suppressor/regulatory
T cells, which in turn release immunosuppressive cytokines. As the
lymph node metastasis develops, the measurements of immuno-
suppression markers significantly decrease. This may directly
reflect the substantial increase of tumour infiltrates in comparison
to residual lymphoid tissue, rendering the tissue type similar to
primary melanoma rather than lymphatic tissue. Replacement of
active lymph nodes by melanoma may also mean the strong local
immunosuppression is no longer necessary. Nevertheless, despite
cessation of TGFb2 production, the tolerogenic DCs are still
present in numbers comparable with primary skin melanomas.
Their immunosuppressive activity might then further support
immune evasion by melanoma.
If tumour-associated peripheral DCs are indeed responsible for
tumour-derived local immunosuppression, and enable the mela-
noma spread to preconditioned lymph nodes, this has considerable
implications for the development of immunotherapy. Reversal
of the tolerising effect exerted by DCs could be successful in
preventing the onset of melanoma metastases, and substantially
support action of other anti-melanoma vaccines. Indeed, vaccines
using DC-specific immune adjuvant (particularly GM-CSF) can
alter the number and activation status of DCs residing in
melanoma SLN (Lana et al, 2001; Lee et al, 2005) and can induce
the activation of peripheral blood lymphocytes resulting in some
positive clinical responses (Vuylsteke et al, 2006). Ultimately, to
enable any effector cell to act, either by means of an anti-
melanoma immune vaccine or by the natural immune response,
DC-mediated local immunosuppression in melanoma must be
reversed. This hypothesis could further be investigated in a series
of functional experiments with tolerogenic DCs and suppressive/
regulatory T lymphocytes, to evaluate the exact mechanism of
melanoma-associated early immunosuppression, and possibly
discover ways to overcome it.
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